Let’s put out a shameless health tech prediction.
-
Faron
The start of the next phase for Bexcombo and Matins aided by biomarkers and the expansion of Bexmab to Phase II. Additionally, news on partnering deals is expected. -
Herantis
The share price has drifted down since Lymfactin and rhCDNF were discontinued, which has increased the company’s risk. All chips are now on HER-096, with Phase I trials being conducted during 2023. Preliminary preclinical data looks promising. -
Optomed
FDA approval, so that sales to the US can be started.